₹50.30
−4.91%NSE close, 16 Nov 2026
+95.72%
VILIN BIO MED is a small cap company, listed on NSE SME under the symbol VILINBIO. At ₹50.30 a share, the market values the whole company at ₹77 crore. NSE SME is the exchange's platform for small and medium companies, which report their results every half year.
In FY26, it reported sales of ₹42 crore and a net profit of ₹2 crore, an operating margin of 7.5%.
The market values the company at 25.1 times its profit over the last twelve months and 2.59 times its book value; its return on equity is 10.3% and it has almost no borrowings.
Promoters hold 56.65% of the shares. Foreign institutions hold 0.13%, and domestic institutions, mutual funds among them, 0.00%.
Over the past year the share price has risen 89.8%, and it is 17.5% below its 52-week high.
Listed on NSE SME, the platform for small and medium companies: its shares trade in large lots and often thinly, so the price can move sharply on a few trades, and companies file results every half year.
₹ crore. Consolidated figures where the company filed them, standalone otherwise (marked S).
| Line | Sep 2023 S | 6M to Mar 2024 S | Sep 2024 S | 6M to Mar 2025 S | 6M to Sep 2025 S | 6M to Mar 2026 S | 6M to Sep 2026 |
|---|---|---|---|---|---|---|---|
| Sales |
The financial results for the period ended September 30, 2026.
That, being listed on the NSE Emerge Platform, the Company is exempt from the applicable Corporate Governance requirements. However, the Company is voluntarily submitting the Integrated Corporate Governance Report for the period ended September 30, 2026.
A copy Srutinizers report of Court Convened General Meeting held on October 15, 2026. Further, the company has informed the Exchange regarding voting results.
Proceedings of Court Convened General Meeting held on October 15, 2026
| 7.7 |
| 8.2 |
| 4.5 |
| 10.3 |
| 9.7 |
| 32.6 |
| 32.6 |
| Expenses | 6.3 | 8.7 | 4.1 | 10.0 | 9.3 | 29.7 | 30.6 |
|---|
| Operating profit | 1.4 | −0.6 | 0.4 | 0.4 | 0.3 | 2.9 | 2.0 |
|---|
| Operating margin | 18.2% | -7.0% | 9.4% | 3.6% | 3.5% | 8.8% | 6.0% |
|---|
| Other income | 0.1 | 0.2 | 0.2 | 0.3 | 0 | 0 | 0 |
|---|
| Interest | 0.4 | 0.4 | 0.4 | 0.4 | 0.1 | 0 | 0 |
|---|
| Depreciation | 0.1 | 0.1 | 0.1 | 0.0 | 0.1 | 0.2 | 0.2 |
|---|
| Profit before tax | 1.0 | −0.8 | 0.2 | 0.2 | 0.2 | 2.7 | 1.8 |
|---|
| Tax | 0.3 | 0 | 0.0 | 0.1 | 0.0 | 0.9 | 0.5 |
|---|
| Net profit | 0.8 | −0.8 | 0.1 | 0.1 | 0.2 | 1.8 | 1.3 |
|---|
| EPS (₹) | 0.55 | 0.00 | 0.00 | 0.07 | 0.11 | 1.26 | 0.84 |
|---|
₹ crore, financial years to March.
| Line | FY24 S | FY25 S | FY26 S |
|---|---|---|---|
| Sales | 15.8 | 14.8 | 42.3 |
| Expenses | 15.0 | 14.0 | 39.1 |
| Operating profit | 0.8 | 0.8 | 3.2 |
| Operating margin | 5.2% | 5.3% | 7.5% |
| Other income | 0.3 | 0.5 | 0 |
| Interest | 0.8 | 0.9 | 0.1 |
| Depreciation | 0.1 | 0.1 | 0.3 |
| Profit before tax | 0.2 | 0.3 | 2.8 |
| Tax | 0.1 | 0.1 | 0.9 |
| Net profit | 0.2 | 0.2 | 1.9 |
| EPS (₹) | 0.12 | 0.16 | 1.37 |
₹ crore, at each year's end and the latest half year.
₹ crore, by financial year, and the latest half year.
| Line | FY24 | FY25 | FY26 | 6M to Sep 2026 |
|---|---|---|---|---|
| From operations | −5.3 | −3.8 | 0.7 | −0.7 |
| From investing | 0.3 | −1.1 | −0.3 | −0.4 |
| From financing | 11.0 | −1.1 | 1.0 | −0.2 |
| Spent on fixed assets | – | −1.6 | −0.3 | −0.4 |
| Free cash flow | – | −5.4 | 0.4 | −1.1 |
Margins, returns, debt, tax and cash.
| Line | FY24 | FY25 | FY26 |
|---|---|---|---|
| Net margin | 1.0% | 1.5% | 4.6% |
| Operating margin | 5.2% | 5.3% | 7.5% |
| Return on equity | – | 1.0% | 6.8% |
| Return on capital employed | – | 4.5% | 10.2% |
| Return on assets | – | 0.8% | 5.5% |
| Debt to equity | – | 0.11 | 0.01 |
| Interest coverage | 1.30 | 1.40 | 41.60 |
| Debt to assets | – | 0.09 | 0.01 |
| Current ratio | – | 2.75 | 4.25 |
| Quick ratio | – | 1.78 | 3.13 |
| Cash ratio | – | 0.01 | 0.23 |
| Asset turnover | – | 0.53 | 1.21 |
| Fixed asset turnover | – | 11.57 | 14.72 |
| Inventory turnover | – | 3.10 | 5.20 |
| Receivables turnover | – | 2.30 | 2.60 |
| Gross margin | – | 9.0% | 11.0% |
| Cash from operations to profit | -3,312.0% | -1,741.0% | 36.0% |
| Effective tax rate | 26.1% | 25.8% | 32.0% |
Outcome of Board Meeting held on September 15, 2026.
General Updates
General Updates
Scrutinizer Report and Voting Results
A copy Srutinizers report of Annual General Meeting held on September 02, 2026. Further, the company has informed the Exchange regarding voting results.
Proceedings of Annual General Meeting held on September 02, 2026
Outcome of Board Meeting held on August 10, 2026.
Vilin Bio Med Limited has informed the Exchange regarding Updates